6/28/23, 11:22 PM NEAT-HFpEF Pathway Feedback Search Clinical Topics Home Studies NEAT HFpEF NEAT HFpEF Disease Heart failure Trial question What is the role of isosorbide mononitrate in patients with HF and a preserved ejection fraction? Study design Multi-center Double blinded RCT Population Characteristics of study participants 57.0% female N = 110 43.0% male 110 patients (63 female, 47 male) Inclusion criteria: patients with HF and a preserved ejection fraction Key exclusion criteria: systolic BP < 110 mmHg or > 180 mmHg or a previous adverse reaction to or current use of long-term nitrate or phosphodiesterase type 5 inhibitor therapy Interventions N=51 isosorbide mononitrate (6-week dose escalation from 30 mg to 60 mg to 120 mg once daily) N=59 placebo (matching placebo once daily for 6 weeks) Primary outcome Hours of activity per day 9.31 9 3 9 01 https://web.pathway.md/studies/recQbl34lh5Ir5EkI 1/2 6/28/23, 11:22 PM NEAT-HFpEF Pathway 9 3 9.3 9.01 7.0 4.7 2.3 Significant decrease 0.0 Isosorbide mononitrate Placebo Significant decrease in hours of activity per day (9.01 vs. 9.31; difference -30, 95% CI -0.55 to -0.05) Secondary outcomes Significant decrease in activity during all dose regimens (9185 vs. 9623; difference -439, 95% CI -792 to -86) Conclusion In patients with HF and a preserved ejection fraction, isosorbide mononitrate was not superior to placebo with respect to hours of activity per day. Reference Redfield MM, Anstrom KJ, Levine JA et al. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2015 Dec 10;373(24):2314-24. Open reference URL https://web.pathway.md/studies/recQbl34lh5Ir5EkI 2/2